Biobetter developer Alteogen said Thursday it has signed a contract with Intas Pharmaceutical, an India-based multinational pharmaceutical company, to transfer technology that converts intravenous (IV) injections into subcutaneous (SC) injections.

Alteogen will transfer its ALT-B4 technology to Intas to develop two of its IV biopharmaceutical products into SC injections and then commercialize them early in the global market, except for three Asian countries.

A company official said they could not disclose the information on the three excluded countries due to a confidentiality agreement.

Intas will pay Alteogen a $6 million upfront fee and up to $190 billion in milestone payments depending on clinical development, sales permit, and sales performance. If Intas commercializes the two SV biopharmaceutical products using ALT-B4, Alteogen can also receive up to 10 percent or more of the total sales in royalties depending on sales size.

The amount of ALT-B4 for clinical development and commercial sale combined with antibody and bioproducts is produced and supplied under the responsibility of Alteogen.

“We are happy to sign a contract with Intas, which is growing rapidly in the generic medicine field,” Alteogen CEO Park Soon-jae said. “For the benefit of patients, SC versions of the two blockbuster bioproducts will be released early using the company’s technology.”

Alteogen’s ALT-B4 is a new technology that enhances the protein's stability by increasing thermal stability while maintaining the unique action mechanism and enzyme activity of already known human hyaluronidase with protein engineering technology.